A U.S. Retrospective Database Analysis Evaluating the Comparative Effectiveness of Budesonide/Formoterol (BFC) vs. Fluticasone/Salmeterol (FSC) Combination in Patients With COPD.
Phase of Trial: Phase IV
Latest Information Update: 30 Jun 2014
Price : $35 *
At a glance
- Drugs Budesonide/formoterol (Primary) ; Salmeterol/fluticasone propionate
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 14 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Dec 2013 Planned End Date changed from 1 Feb 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 30 Aug 2013 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.